PBE News and Press, Invesco Dynamic Biotech & Genome From 07/08/22

Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Why the economy, practically speaking, may already be in recession. Why defensive sectors may be worth a closer look in the current environment. Market sentiment might be bearish, but that doesn't mean there aren't opportunities. Aggressive moves by central banks...

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...

Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023. Results from the p...

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...

BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame. However, convincing proof of concept is another year away. Bicycle Therapeutics plc ( BCYC ) is co-founded by Nobel Prize winning molecular biologist Dr. Greg Winter, who is...

Rocket is running a number of successful rare disease programs. Their data so far is excellent. They have a decent cash runway. Rocket Pharmaceuticals, Inc. ( RCKT ) aims to cure rare diseases using gene therapy. Its pipeline looks like this: PIPELINE ...

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line. Here, they have abysmally failed to make any money. Oyster Point Pharma, Inc. (OYST) has an approved p...

Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027. Interim results from the phase 2 MOMENTUM st...